# COBRA (NCT04068103)

> Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04068103
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: NRG Oncology
- Conditions: Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v8
- Interventions: Capecitabine; Fluorouracil; Leucovorin; Leucovorin Calcium; Oxaliplatin; Patient Observation
- Enrollment: 635
- Primary outcome: Clearance of Circulating Tumor Deoxyribonucleic Acid (ctDNA) (to Undetectable Levels) for the "Baseline ctDNA Detected" Patient Subset (Phase II)
- Primary outcome: Recurrence-free Survival (RFS) the "Baseline ctDNA Detected" Patient Subset (Phase III)

## Indexed commentary on COBRA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cobra-nct04068103